@article{820c6812d6b54fb885957b1b97da76bf,
title = "Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA",
abstract = "Aim: This study evaluated the effectiveness of lenvatinib monotherapy for first-line treatment of unresectable hepatocellular carcinoma (uHCC) in a real-world setting. Materials & methods: This retrospective cohort study included patients who initiated lenvatinib monotherapy as first-line treatment for uHCC (n = 233). Clinical outcomes included provider-reported best response, progression-free survival (PFS) and overall survival (OS). PFS and OS were estimated using Kaplan-Meier methods. Results: Most patients (67.8%) were male. A total of 44.6% had Child-Pugh A and 39.1% had Child-Pugh B. Dose reductions were reported in 9%. Median PFS and OS were not reached. At 6 and 12 months, landmark PFS were 85.1 and 64.9%, respectively; landmark OS were 91.8 and 72.6%, respectively. Conclusion: These results affirm the clinical effectiveness of first-line lenvatinib monotherapy in uHCC. ",
keywords = "chart review, hepatocellular carcinoma, lenvatinib, real-world data, survival analysis",
author = "Singal, {Amit G.} and Nagar, {Saurabh P.} and Abby Hitchens and Davis, {Keith L.} and Shrividya Iyer",
note = "Funding Information: This study was funded by Eisai, Inc. Authors affiliated with Eisai, Inc., participated in designing the study, interpreting the data, writing the manuscript and approved the final version for publication. KL Davis, A Hitchens and SP Nagar are salaried employees of RTI Health Solutions, and this study was performed under a research contract between RTI Health Solutions and Eisai, Inc. S Iyer is an employee of Eisai, Inc. AG Singal has been on advisory boards and served as a consultant for Genentech, Bayer, Eisai, BMS, Exelixis, AstraZeneca and TARGET RWE. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. T Barrett of RTI Health Solutions provided medical writing support, which was funded by Eisai, Inc. Publisher Copyright: {\textcopyright} 2021 Future Oncology. All rights reserved.",
year = "2021",
month = jul,
doi = "10.2217/fon-2021-0242",
language = "English (US)",
volume = "17",
pages = "2759--2768",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "21",
}